Smartphone-based Incentives Intervention to Increase Smoking Cessation During Pregnancy
Examining a Digital Perinatal Smoking-Cessation Intervention
Cigarette smoking is the leading preventable cause of poor pregnancy outcomes in the U.S. and a problem for which more effective and easy-to-access treatments are much needed. This study examines whether outcomes achieved with recommended clinical practices (referral to state tobacco Quitline with follow-up and further referrals for those continuing to smoke) can be improved by also offering financial incentives delivered through a smartphone for maternal smoking abstinence.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Pregnant women residing in the U.S. who currently smoke cigarettes and are interested in quitting will be recruited nationally and randomly assigned to what is considered clinical best practices (BP) (referral to state tobacco Quitline with follow-up and further referrals for those continuing to smoke) or best practices in combination with financial incentives (BP+FI). Women assigned to the BP+FI treatment will have opportunities to earn financial incentives by abstaining from smoking during pregnancy and for 3 months after delivering their baby (total possible incentives is $750.00). Women will demonstrate that they have abstained by taking brief salivary cotinine tests using a smartphone or equivalent device. Incentives for abstaining are electronically added to a study-provided debit card. Participation and all results are strictly confidential. Participants in both treatment conditions will be financially compensated for study participation with potential earnings of $525.00. Total potential earnings for those assigned to BP is $525.00 and for those assigned to BP+FI it is $1,275 ($525 for study participation and $750 in incentives for quitting smoking).
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Stephen T Higgins, PhD
- Número de teléfono: 802-656-9615
- Correo electrónico: stephen.higgins@uvm.edu
Copia de seguridad de contactos de estudio
- Nombre: Katya A Nolder, PhD
- Número de teléfono: 802-656-9615
- Correo electrónico: katya.nolder@uvm.edu
Ubicaciones de estudio
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05464
- University of Vermont
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 18 yrs of age
- Reports current pregnancy of </= 25 weeks gestational age
- Consents to allow us to confirm pregnancy with healthcare provider
- Reports current smoking when learned of current pregnancy
- Reports smoking in the 7 days prior to screening
- Reports of smoking in past 7 days is confirmed by a salivary cotinine test
- Owns a digital phone or tablet
- Sufficiently fluent in English to complete study tasks
Exclusion Criteria:
- Reports current or prior mental or medical condition that may interfere with study participation
- Reports current opioid agonist treatment for opioid use disorder
- Current use of prescribed opioid, antipsychotic, or stimulant medications
- Live with someone who is enrolled in the study
- Reside in a group home
- Currently participating in another study that provides financial incentives
- Legal problems that may result in incarceration within the next year
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Best Practices
Best Practices (BP) entails the 5As including referral to the state tobacco Quitline and further referral for those continuing to smoke. |
Participants receive the 5As including a staff referral to the state tobacco quitline. |
|
Experimental: Best Practices plus Financial Incentives
Best practices plus providing financial incentives contingent on biochemically verified abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks postpartum. |
Participants receive the 5As including a staff referral to the state tobacco quitline. Participants receive financial incentives contingent on biochemically verified abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks postpartum. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Antepartum smoking abstinence
Periodo de tiempo: Antepartum period is from study entry through infant delivery which is typically about 24 weeks duration.
|
The primary outcome is whether women randomly assigned to the two treatment groups differ in the percentage who abstain from smoking across an early (< 25 weeks gestation) and late (> 25 weeks gestation) antepartum assessments defined by the percentage of participants assigned to each condition who report no smoking in the past 7 days and submit of a salivary cotinine sample that tests negative for recent smoking. |
Antepartum period is from study entry through infant delivery which is typically about 24 weeks duration.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postpartum smoking abstinence
Periodo de tiempo: 2-weeks, 6-weeks, 12-weeks following delivery.
|
Smoking abstinence at 2, 6, and 12 weeks postpartum defined as the percent of participants randomly assigned to each of the two treatment conditions who report no smoking in the past 7 days and submit of a salivary cotinine test sample that is negative for recent smoking. |
2-weeks, 6-weeks, 12-weeks following delivery.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Birth Outcomes
Periodo de tiempo: Birth record at time of delivery
|
Birth outcomes calculated from data extracted from the birth delivery reports include mean birth weight, % low birth weight deliveries (< 2500 g), mean gestational age at delivery, % premature deliveries (< 37 weeks), incidence of Neonatal Intensive Care Unit (NICU) admissions, and mean length of stay per NICU admission. |
Birth record at time of delivery
|
|
Treatment Acceptability Questionnaire
Periodo de tiempo: 24 weeks following delivery
|
Participants in both treatment conditions will complete the Treatment Acceptance Questionnaire (TAQ) at the 24-weeks postpartum assessment. The TAQ will query participants about the (1) ease of use of their assigned intervention; (2) helpfulness, and (3) convenience of the intervention; (4) whether the intervention facilitated engagement with smoking-cessation treatment; (5) whether the intervention was fair, (6) fun, (7) or helpful in abstaining from smoking during pregnancy, (8) after the baby was born, and (9) longer-term; and (10) whether they would recommend the treatment that they received to others. All responses will be made using a 100-point visual analogue scale with higher scores represent greater acceptance. |
24 weeks following delivery
|
|
Smoking abstinence at 24-weeks postpartum
Periodo de tiempo: 24 weeks after delivery
|
Participants report no smoking in the past 7 days that is confirmed with a negative salivary cotinine test |
24 weeks after delivery
|
|
Cost effectiveness
Periodo de tiempo: 24-weeks postpartum
|
A cost-effectiveness analysis of adding financial incentives to the Best-Practices intervention will be conducted. |
24-weeks postpartum
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Stephen T Higgins, PhD, University of Vermont
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STUDY00004146
- UG3DA065232 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Investigators are willing to share data once the study is completed and results are published in a peer-reviewed journal. Sharing is conditional on those requesting having a scientific rationale for their request.
Marco de tiempo para compartir IPD
Upon study completion and publication of the primary trial outcomes in a peer-reviewed journal and planned secondary outcomes (e.g., birth outcomes, cost-effectiveness). Anticipated start date is 3 years after trial completion. Anticipated end date is 5 years after study completion.
Criterios de acceso compartido de IPD
Briefly, this trial will use the standard processing and documentation protocols adopted by the Inter-university Consortium for Political and Social Research (ICPSR). All shared data, metadata, and associated documentation will be deposited via the National Addiction & HIV Data Archive Program (NAHDAP), which is hosted by ICPSR. The scientific data provided by our trial will be findable via a study digital object identifier (DOI) minted by ICPSR. Users of our shared scientific data must register with ICPSR and agree to the Terms of Use, which allows use only for scientific research purposes and aggregate statistical analyses. This is intended to protect research participants and prohibit attempts to identify individual participants. Users must also agree to not redistribute data downloads.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .